Georgina V. Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair, Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, member, Charles Perkins Centre, discusses evaluating pembrolizumab (Keytruda) vs placebo in stage IIB or IIC melanoma.

The phase 3 KEYNOTE-716 study (NCT03553836) is evaluating pembrolizumab vs placebo to determine if 12 months of pembrolizumab can decrease the risk of recurrence and prolong distant metastasis-free survival and overall survival, Long says. At the 2022 ASCO Annual Meeting, the first analysis of the distant metastasis-free survival was presented, showing that pembrolizumab given for 12 months after complete resection of stage IIB or IIC melanoma decreased the risk of distant metastasis by 36% compared with placebo, Long explains.

The landmark 12-month and 24-month rates of distant metastasis-free survival were higher in the pembrolizumab arm compared with the placebo arm, Long adds. Moreover, all key subgroups s

Videos

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses evaluating pembrolizumab vs placebo in stage IIB or IIC melanoma.


Dr. Long on Evaluating Adjuvant Pembrolizumab vs Placebo in Melanoma

Georgina V. Long, BSc, PhD, MBBS, chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute of Australia (MIA) and Royal North Shore Hospital, University of Australia, discusses the patients with melanoma who respond best to the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist).

According to the pooled analysis results of the COMBI-d study, the 3-year overall survival (OS) of patients on the combination was 44%. The patient profile of those who performed well on this regimen is similar to those who do well on immunotherapy agents. Predictive factors of long-term OS were: normal lactate dehydrogenase at baseline, low sum of diameter of metastases at baseline, and less than 3 organ sites.


Georgina V. Long, BSc, PhD, MBBS, chair of Melanoma Medical Oncology and Translational Research at the Melanoma Institute of Australia (MIA) and Royal North Shore Hospital, University of Australia, discusses the patients with melanoma who respond best to the combination of dabrafenib plus trametinib.

Georgina V. Long, BSc, PhD, MBBS

Articles

Dr. Long on Evaluating Adjuvant Pembrolizumab vs Placebo in Melanoma

Dr. Long on Treating Melanoma With Dabrafenib Plus Trametinib